POLB — Poolbeg Pharma Income Statement
0.000.00%
Last trade - 00:00- £14.50m
- £4.44m
Annual income statement for Poolbeg Pharma, fiscal year end - December 31st, GBP millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final |
| Revenue | |||
| Total Revenue | 0 | 0 | 0 |
| Cost of Revenue | |||
| Gross Profit | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||
| Research And Development | |||
| Unusual Expense / Income | |||
| Other Operating Expenses | |||
| Total Operating Expenses | 2.34 | 4.99 | 5.04 |
| Operating Profit | -2.34 | -4.99 | -5.04 |
| Total Net Non Operating Interest Income / Expense | |||
| Net Income Before Taxes | -2.34 | -4.78 | -4.5 |
| Provision for Income Taxes | |||
| Net Income After Taxes | -2.34 | -4.69 | -3.93 |
| Net Income Before Extraordinary Items | |||
| Net Income | -2.34 | -4.69 | -3.93 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||
| Income Available to Common Shareholders Including Extraordinary Items | |||
| Diluted Net Income | -2.34 | -4.69 | -3.93 |
| Diluted Weighted Average Shares | |||
| Basic EPS Including Extraordinary Items | |||
| Diluted EPS Including Extraordinary Items | |||
| Diluted EPS Excluding Extraordinary Items | |||
| Normalised Income Before Taxes | |||
| Normalised Income After Taxes | |||
| Normalised Income Available to Common Shareholders | |||
| Diluted Normalised EPS | -0.005 | -0.009 | -0.007 |
| Dividends per Share |